Related Experiment Video
Updated: Jun 20, 2026
04:11
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Hepatitis B virus resistance to nucleos(t)ide analogues
Fabien Zoulim1, Stephen Locarnini
1INSERM, U871, Lyon, France. fabien.zoulim@inserm.fr
Gastroenterology
|September 10, 2009
Summary
Nucleos(t)ide analogs (NA) treat chronic hepatitis B (CHB), but drug-resistant hepatitis B virus (HBV) mutants emerge. Understanding cross-resistance is key to developing effective therapies for CHB patients.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B (CHB) is often treated with nucleos(t)ide analogs (NA).
- Drug-resistant hepatitis B virus (HBV) mutants frequently develop, causing treatment failure and disease progression.
- Limited development of new NA necessitates a deeper understanding of existing agents and resistance mechanisms.
Purpose of the Study:
- To investigate mechanisms of cross-resistance to nucleos(t)ide analogs (NA) in hepatitis B virus (HBV).
- To explore strategies for managing NA resistance in CHB patients.
- To inform the development of more effective therapeutic approaches for CHB.
Main Methods:
- Review of existing research on NA resistance mechanisms and mutant selection.
- Analysis of associations between HBV genotype and resistance phenotype.
- Evaluation of therapeutic strategies for patients experiencing virologic breakthrough or partial response.
Main Results:
- Resistance mutations in HBV polymerase affect envelope proteins, impacting infectivity, vaccine efficacy, and transmission.
- Cross-resistance profiles for common HBV mutants have been determined.
- Genotyping assays can guide therapy adaptation for CHB patients.
Conclusions:
- Effective management of CHB requires understanding NA cross-resistance and adapting therapy based on HBV genotype.
- Early intervention with a second NA can be successful for patients with virologic breakthrough.
- Prioritizing potent antivirals with a high resistance barrier and continued research into novel targets and combination therapies are crucial for combating NA resistance.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:29Viruses with RNA Genomes
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...